Clinical Trial: Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of Recombinant Botulinum Toxin Type A for Injection (Sf9 Cell, 150 kD Native Amino Acid Sequence) in Trial Participants with Persistent Erythema of Rosacea with Paroxysmal Flushing (China)

China, Nov. 10 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of Recombinant Botulinum Toxin Type A for Injection (Sf9 Cell, 150 kD Native Amino Acid Sequence) in Trial Participants with Persistent Erythema of Rosacea with Paroxysmal Flushing'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600136199

Registration Time: 2026/11/06

Type: Interventional study

Primary Sponsor: West China Hospital of Sichuan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=348971

Published by HT Digital Content Services with permission from Hea...